Results 61 to 70 of about 19,833 (230)

Infectious Complications Reporting in Common Variable Immunodeficiency: A Systematic Review and Meta-analysis

Oman Medical Journal, 2020
Objectives: Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by hypogammaglobulinemia and increased susceptibility to recurrent infections.
Hamed Zainaldain, Fatema Sadaat Rizvi, Hosein Rafiemanesh, Mahla Alizadeh, Mahnaz Jamee, Sara Mohammadi, Fatemeh Kiaee, Hamed Mohammadi, Farhad Babaie, Reza Yazdani, Hassan Abolhassani, Asghar Aghamohammadi, Gholamreza Azizi   +12 more
doaj   +1 more source

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. [PDF]

, 2009
We observed that high-dose methylprednisolone (HDMP) and rituximab was well tolerated and had promising activity when used in combination to treat patients with fludarabine-refractory chronic lymphocytic leukemia (CLL).
Bole, J, Castro, JE, Jain, S, James, DF, Kipps, TJ, Rassenti, L, Sandoval-Sus, JD   +6 more
core  

CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients [PDF]

, 2016
Intravenous ganciclovir and, increasingly, oral valganciclovir are now considered the mainstay of treatment for cytomegalovirus (CMV) infection or CMV disease.
Allison, Asberg, Boivin, Carbone, Chou, Cremer, Crumpacker, Eid, Eid, Emery, Fellay, Gagermeier, Gupta, Humar, Humar, Humar, Isada, Jaksch, Keay, Kijpittayarit-Arthurs, Kneidinger, Kotton, Kruger, Li, Limaye, Limaye, Mendez-Eirin, Minces, Novick, Perrottet, Roman, Rouphael, Sarmiento, Schoeppler, Zamora   +34 more
core   +3 more sources

Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency

JEADV Clinical Practice, EarlyView.
ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz, Lars Matthies, Andrea Vanegas Ramirez   +2 more
wiley   +1 more source

Brain abscess following rituximab infusion in a patient with pemphigus vulgaris. [PDF]

, 2015
BackgroundImmunocompromised patients are at increased risk for developing meningitis or, rarely, brain abscess with opportunistic organisms like Listeria monocytogenes.Case reportA 52 year-old Saudi Arabian woman who was diagnosed with pemphigus vulgaris
Al-Harbi, Talal M, Al-Muammar, Shahad A, Ellis, Ronald J   +2 more
core   +2 more sources

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, EarlyView.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Fatal lymphoproliferation and acute monocytic leukemia-like disease following infectious mononucleosis in the elderly [PDF]

, 1981
Three elderly patients are reported, in whom serologically confirmed recent infectious mononucleosis is followed by fatal lymphoproliferation (case 1), by acute monocytic leukemia (case 2), and by acute probably monocytic leukemia (case 3)
Deinhardt, F., Hehlmann, R., Schmid, M., Walther, B., Wolf, Hans J., Zöllner, N.   +5 more
core   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

Strongyloides Hyperinfection and Hypogammaglobulinemia [PDF]

Clinical and Vaccine Immunology, 2005
ABSTRACT We report strongyloides hyperinfection in two patients with generalized hypogammaglobulinemia from multiple myeloma and nephrotic syndrome, despite a significant strongyloides-specific immunoglobulin G (IgG) response. In contrast to reports on animals, where human IgG was shown to be a protective antibody, our observation suggests ...
Seet, R.C.S., Lau, L.G., Tambyah, P.A.
openaire   +2 more sources